CLOs on the Move

HeartBeam

www.heartbeam.com

 
HeartBeam, Inc. (NASDAQ: BEAT) is a development stage digital healthcare company with proprietary ECG telemedicine technology that will redefine the way high risk cardiovascular patients are diagnosed in an ambulatory setting at any time and any place. Its breakthrough solution employs a reusable, credit card sized, 3D vector ECG recording device and cloud-based software capable of assisting a physician in diagnosing a wide range of cardiovascular disease. HeartBeam is initially focusing on a huge unmet need of helping diagnose heart attacks in patients outside of a medical institution. No single lead ECG technology can offer this value to patients and ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Galil Medical

Galil Medical is a global leader in generating innovative cryotherapy solutions. Our technologies are delivered through multiple physician specialties; we are focused on conditions affecting bone, kidney, liver, lung and prostate as well as targeted pain applications.

Enerspect Medical Solutions

Enerspect Medical Solutions is a Henderson, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Biodirection

NanoDx Inc. is a privately held medical device company developing novel and rapid point-of-care technologies for the objective diagnosis and management of concussion and other traumatic brain injury (TBI).

MCS-Medical Consulting and Solutions

MCS-Medical Consulting & Solutions is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Dthera

Dthera™ Sciences (OTCQB:DTHR) is the leading digital therapeutic company focusing on the elderly. The San Diego-based, publicly traded company is working to improve the lives of seniors and individuals suffering from neurodegenerative diseases, as well as those who care for them. It has two core products: ReminX™, a commercially available consumer health product for individuals suffering from social isolation and dementia; and DTHR-ALZ, and a development-stage product that has been granted Breakthrough Device designation by the FDA for the mitigation of the symptoms of agitation and depression associated with Alzheimer`s disease.